ANKASCIN® 568-R red yeast rice extract shows benefits to manage total cholesterol and LDL-C

cardiovascualr health ankascin

The first clinical study, which has been published in the Journal of Food and Drug Analysis, documents that ANKASCIN® 568-R is effective in reducing subjects’ serum cholesterol and low-density lipoprotein cholesterol (LDL-C) to nearly desirable levels in as little as 4 weeks and were maintained in 8 weeks.

Forty subjects (Inclusion criteria: LDL-C in the range of 130-190 mg/dL and serum cholesterol greater than 180 mg/dL) completed the double-blind, placebo-controlled randomized 12-week study. The administration group took 110 mg ANKASCIN® 568-R/one capsule/day for eight weeks.

After four weeks of treatment (110 mg ANKASCIN® 568-R/day), the changes in the lipid levels showed that the active products had a more favorable effect than the placebo. Compared to the baseline, statistically significant decreases of 11.9% and 19.0% were observed in TC and LDL-C levels, respectively (p < 0.05 for all pairs). This study demonstrated that subjects administered 110 mg of ANKASCIN® 568-R for more than four weeks exhibited a significant reduction in serum TC and LDL-C levels.

To assess the safety of this ingredient, scientists assayed aspartate transaminase (AST) and alanine aminotransferase (ALT) levels in the liver, and blood urea nitrogen (BUN), creatinine, and uric acid levels in the kidney. The results imply no significant effect on renal metabolism and physiological function.

These results indicate that supplementation of ANKASCIN® 568-R reduces the risks of serum TC and LDL-C levels. People can benefit from compelling effects of ANKASCIN® 568-R, efficacious and science-supported red yeast rice ingredient. ANKASCIN® 568-R is available worldwide now.

John Pan, President of SunWay Biotech commented that “Efficacy and scientific evidence is the top priority to drive consumers to buy the dietary supplements; therefore, science-backed is important for each product. ANKASCIN® 568-R is backed by robust science, and it is the commitment to provide long-term care for people worldwide, thereby making a different life in this modern world.”

For more information, please contact us:



A Randomized, double-blind clinical study of the effects of ANKASCIN 568 Plus on blood lipids regulation. Pan et al., Journal of Food and Drug Analysis 2018 Jan; 26(1):393-400. (link)


Disclaimer: This communication is only intended for business-to-business. Nothing on this page is meant to be perceived as an approved claim by regulatory authorities.